Syncona makes further $80 million commitment to Freeline
Summary
The company has reported that the first two patients in its ongoing Phase 1/2 trial who were treated with the lowest dose[3] have shown that Factor IX (FIX) activity remains stable and consistent at 40.5±4.5% through weeks 66 and 74, respectively, post administration. Freeline is currently seeking to identify the optimal dosing regimen to deliver FIX activity consistently in the normal range for all patients and expects to report further data on this trial in the first quarter of 2020. The company also has disclosed pre-clinical programmes targeting Gaucher Disease and Haemophilia A, which are part of a broad pipeline of systemic disorders where high protein expression is crucial to providing functional cures for patients. Brian Silver, Chief Financial Officer of Freeline, said: “The potential of gene therapy to change patients’ lives has never been greater, and we are delighted to have secured this Series C financing from our founding investor, Syncona. We are continuing with dose optimisation and remain on track to provide a clinical data update by financial year end.” Freeline is a privately-held clinical-stage biotechnology company focused on AAV based gene therapy targeting the liver.